2019 was a year of innovation and disruption in the life sciences industry. From artificial intelligence to cell and gene therapy, and from generics and biosimilars to geopolitics and healthcare reform, PharmaBoardroom is proud to have collaborated with industry thought leaders to publish their insights on the year’s top trends in pharma and healthcare. Here we present ten opinion pieces published in 2019. Read more from our contributors here.
Three Basic Truths About the US Healthcare System
AstraZeneca’s Senior Vice President of US Market Access Rick R. Suarez takes a deeper look at US healthcare system challenges and suggests that cross-sector collaboration, rather than blame-shifting, is what will effect positive change.
The Cell & Gene Therapy Market: Coming into Its Own
David H. Crean is the managing director for Objective Capital Partners, a middle market investment banking firm located in Southern California, where he leads the firm’s M&A, partnering and capital financing transactions with life science and healthcare clients. In this article Crean highlights trends in the cell and gene therapy market and why now is the time to invest in these cutting-edge treatments.
Forging a New Path to Commercialization for Cell and Gene Therapies
In a similar vein, Greg Reh, Global Life Sciences & Health Care industry leader for Deloitte, shares how pharma companies should prepare for innovations in the manufacturing, pricing and reimbursement of personalized cell and gene therapies and the challenges these disruptive innovations will present.
From Hype to Health: Delivering on the Promise of AI in Biopharma
Krishna Cheriath serves as chief data officer at Bristol-Myers Squibb. Cheriath is the company’s data strategist and adviser, steward for improving data quality, an evangelist for data sharing, data-driven innovations and data ethics and standards, and lead technologist for data and analytic automation. From this vantage point he has observed the gradual adoption of artificial intelligence in healthcare and has seen how AI is already transforming the industry.
Real-World Evidence – A Game Changer for Pharma
Nawal Roy is the founder and CEO of Holmusk, a company dedicated to building one of the world’s largest real-world evidence platforms for neurosciences. Roy discusses tangible ways that pharmaceutical companies can use real-world evidence to increase effectiveness in product life-cycle management.
Proposed Solutions to the Access Challenges Facing Cancer Medicines in Europe
Janssen’s EMEA market access head Martin Price leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Janssen’s new products and indications. In this article Price outlines access challenges that cancer patients in Europe face, including time between regulatory approval and patient access as well as barriers to timely reimbursement. Price suggests some regulatory changes that should be made in order to speed up access to transformational cancer therapies.
USA: The Biosimilars Trade Opportunity
Chester “Chip” Davis, Jr. is the President and Chief Executive Officer of the Association for Accessible Medicines (AAM), the nation’s leading trade association for manufacturers and distributors of generic prescription drugs, manufacturers of bulk active pharmaceutical chemicals and suppliers of other goods and services to the generic drug industry. Continuing on the topic of patient access, Davis argues for greater provision for access to affordable medicines – including biosimilars – within the trade agreements, and how such provisions would bolster the development of biosimilars.
Japan: Reforming Healthcare in the Age of Ageing
Asia also faces a growing need to increase patient access to innovative medicines and in Japan, this need is related to its ageing population. Janssen Japan’s Chris Hourigan makes the case for increasing access to innovative medicines to combat escalating healthcare costs.
Why Invest in Rare Diseases & Orphan Drugs?
David H. Crean of Objective Capital Partners makes the case for why orphan drugs deserve to be invested in, taking a look at the forecast of orphan drug sales over the next five years. Crean also highlights companies currently leading the rare disease drug market.
The Ideal Pharma Country Manager: China
Lydia Guo, Grace Zhao and Mendy Zhang of executive search firm Egon Zehnder outline why country managers of multinational pharma affiliates should exhibit curiosity, insight, engagement and determination and highlight some of the latest trends affecting the Chinese pharma sector.
Add Your Comment
You must be logged in to post a comment.